Saturday, February 27, 2016 7:39:55 PM
AVAX Technologies, Inc. is a development stage biotechnology firm specializing in the development and commercialization of vaccine therapies and other technologies for the treatment of cancer. The company has a market cap of $1.39 million. The Company’s vaccine consists of autologous (the patient’s own) cancer cells that have been treated with a chemical (haptenized) to make them more visible to the patient’s immune system. It currently has negative earnings. AVAX refer to its cancer vaccine technology as autologous cell (AC) vaccine platform.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM